A mood-stabilizing drug prescribed to many patients with schizophrenia or bipolar disorder may decrease negative symptoms for people with a certain variant of the COMT gene.
The biomarker is an important step toward understanding and treating one of the most devastating symptoms of schizophrenia.
Researchers have found that treatment with very low doses of a dopamine-1 receptor (D1R) agonist was not effective in reducing the cognitive and negative symptoms of schizophrenia.
In studies in mice, Zuckerman Institute researchers have discovered a way to restore memory deficits found in schizophrenia by regrowing lost neuronal connections.
A new computational analysis identifies gene networks involved in schizophrenia -- and a connection with autism.